Equities

Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)22.07
  • Today's Change6.63 / 42.94%
  • Shares traded1.32m
  • 1 Year change+147.98%
  • Beta1.0814
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments5758125
Total Receivables, Net314015
Total Inventory5.529.126.62
Prepaid expenses6.268.267.41
Other current assets, total------
Total current assets99116154
Property, plant & equipment, net1.032.7912
Goodwill, net------
Intangibles, net1415--
Long term investments------
Note receivable - long term------
Other long term assets3.060.640.97
Total assets117134167
LIABILITIES
Accounts payable7.14233.80
Accrued expenses182444
Notes payable/short-term debt000
Current portion long-term debt/capital leases7.23----
Other current liabilities, total211916
Total current liabilities536564
Total long term debt523920
Total debt603920
Deferred income tax------
Minority interest------
Other liabilities, total404353
Total liabilities146148137
SHAREHOLDERS EQUITY
Common stock0.180.170.17
Additional paid-in capital1,3791,3691,354
Retained earnings (accumulated deficit)(1408)(1382)(1324)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.01(0.15)(0.1)
Total equity(29)(14)30
Total liabilities & shareholders' equity117134167
Total common shares outstanding171717
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.